Wikidata

(Q63587860)

English

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

clinical trial

In more languages

Statements

title
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations (English)
0 references
medical condition
lymphoma
0 references
sarcoma
0 references
glioma
0 references
neuroblastoma
0 references
osteosarcoma
0 references
rhabdomyosarcoma
0 references
ependymoma
0 references
medulloblastoma
0 references
histiocytosis
0 references
hepatoblastoma
0 references
start time
1 October 2018
0 references
end time
31 December 2025
0 references
number of participants
49
0 references
research site
Mayo Clinic
0 references
Mission Health System
0 references
Vanderbilt University
0 references
Loma Linda University
0 references
University of Miami
0 references
University of Chicago
0 references
minimum age
12 month
0 references
maximum age
21 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63587860&oldid=1857303921"